

10/502244
PCT/EP03/01229



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

REC'D 21 MAR 2003
WIPO PCT

Bescheinigung

Certificate

Attestation

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

The attached documents are exact copies of the European patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécifiée à la page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

02077742.1

PRIORITY
DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

R C van Dijk

BEST AVAILABLE COPY



Anmeldung Nr:
Application no.: 02077742.1
Demande no:

Anmeldetag:
Date of filing: 09.07.02
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

Vlaams Interuniversitair Instituut voor
Biotechnologie (VIB)
Rijvisschestraat 120
9052 Zwijnaarde
BELGIQUE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.
If no title is shown please refer to the description.
Si aucun titre n'est indiqué se referer à la description.)

A novel target to inhibit angiogenesis

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)
revendiquée(s)
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/
Classification internationale des brevets:

A61K39/395

Am Anmeldetag benannte Vertragstaaten/Contracting states designated at date of
filing/Etats contractants désignés lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

A novel target to inhibit angiogenesis

12. 07. 2002

(65)

Field of the invention

The invention relates to the field of pathological angiogenesis. In particular the
5 invention relates to the use of molecules binding to AC133 that can be used for the manufacture of a medicament to prevent angiogenesis.

Background of the invention

The "hemangioblast" is a putative progenitor cell that has the potential to form either
10 endothelial or hematopoietic cells. It exists during embryogenesis in the blood island region of the yolk sac (1), which is therefore the earliest site of hematopoiesis and vasculogenesis. Until recently, vasculogenesis has been thought to be restricted to the yolk sac and the early embryogenesis. However, novel observations have revealed in
15 adulthood a situation consistent with vasculogenesis: endothelial cells derived from angioblasts or "hemangioblasts" previously isolated from peripheral blood or bone marrow are incorporated into sites of neovascularization in physiological and pathological conditions (2-6). In addition, the number of these endothelial cell progenitors increases in the peripheral blood during tissue ischemia or following the administration of VEGF or GM-CSF, a cytokine known to induce mobilization of
20 hematopoietic stem cells from the bone marrow into the peripheral blood (5, 6). Recent studies in humans, dogs, rats, rabbits and mice have indeed indicated the presence of endothelial precursor cells (EPCs) in bone marrow and peripheral blood during adult life which can be mobilized and incorporated into newly formed vessels or are involved in endothelialization of implants (4, 7-13). Interestingly, in all these
25 experiments, EPCs are isolated together with other hematopoietic stem cells by using antibodies directed against hematopoietic stem cell antigens. AC133 is a rather novel human hematopoietic stem cell antigen (14) of unknown physiological or pathological function. AC133, recently designed CD133 (National Center for Biotechnology, 2000) is expressed on lineage non-committed stem and progenitor cells but not on mature
30 peripheral blood cells and umbilical vein derived endothelial cells (15). It is detected on 30-60% of all CD34⁺ cells, including CD34^{bright} cells. This cell population contains CD38^{dim/neg}, HLA-DR⁻, CD117⁺, CD90⁺ cells. AC133⁺ CD34⁺ hematopoietic stem cells

are enriched in Long-Term Culture-Initiating Cells, NOD/SCID repopulating cells and dendritic cell progenitors (16). Subsets of this population express the angiopoietin receptors TIE (67.6%) and TEK (36.8%), Flt-1 (7%), Flt-4 (3.2%), KDR (10.4%), the receptor tyrosine kinase HER-2 (15.4%) and Flt-3 (77.6%). Only few AC133⁺ cells do
5 not co-express CD34: these cells are very small and define a population of unknown delineation (CD71⁻, CD117⁻, CD10⁻, CD38^{low}, CD135⁺, HLA-DR^{high}) (17). In acute myeloid leukemias, AC133 expression is often but not always associated with CD34 expression (18, 19). AC133 is also found on acute lymphoid leukemia blasts and on a subset of CD34⁺ B-cell precursors (20). Flow cytometric analyses of a wide panel of
10 human cell lines showed that only retinoblastoma and teratocarcinoma cell lines express AC133 (21). Recently, AC133 was found to be expressed in EPCs. CD34⁺ cells co-expressing VEGFR-2 and AC133 have been isolated from peripheral blood, cord blood, fetal liver and bone marrow. However, the possible role of AC133 in hematopoiesis and vasculogenesis in the developing embryo and, after birth, in
15 angiogenesis, postnatal vasculogenesis and hematopoietic stem cell trafficking, remains largely unknown. To study in detail the *in vivo* role of AC133 in the present invention AC133 deficient mice were generated. It was surprisingly found that AC133 has a key role in pathological vasculogenesis and/or angiogenesis and that inhibitors of AC133 can be used in therapeutic strategies to inhibit blood vessel formation in
20 various pathological disorders.

Aims and detailed description of the invention

AC133 is a protein of 97 KD with a 5-transmembrane structure (14). The 5-transmembrane structure appears at present restricted to the human AC133, the
25 murine prominin and the related protein of the nematode *C. elegans* (25-28). This structure indicates that these proteins belong to a new class of serpentine receptors. Murine prominin has 60% amino acid homology with AC133 (25). It is not yet clear whether murine prominin is the murine homologue of human AC133, or whether it is a close family member (25, 26). For the sake of clarity the nucleotide sequence of
30 human AC133 is designated here as SEQ ID NO: 1 and the amino acid sequence of human AC133 is designated as SEQ ID NO: 2. The present invention shows that inhibitors of AC133 can be used in therapeutic applications for the prevention of pathological angiogenesis.

Thus the invention provides in one embodiment the use of a molecule which comprises a region specifically binding to AC133 or nucleic acids encoding AC133, for the manufacture of a medicament to treat pathological angiogenesis.

- 5 According to the invention molecules that comprise a region specifically binding to AC133 or nucleic acids encoding AC133 which can be used for the manufacture of a medicament to treat pathological angiogenesis can be chosen from the list comprising an antibody or any fragment thereof binding to AC133, a (synthetic) peptide, a protein, a small molecule specifically binding to AC133 or nucleic acids encoding AC133, a
- 10 ribozyme against nucleic acids encoding AC133, and anti-sense nucleic acids hybridising with nucleic acids encoding AC133.

The term 'antibody' or 'antibodies' relates to an antibody characterized as being specifically directed against AC133 or any functional derivative thereof, with said antibodies being preferably monoclonal antibodies; or an antigen-binding fragment thereof, of the F(ab')₂, F(ab) or single chain Fv type, or any type of recombinant antibody derived thereof. These antibodies of the invention, including specific polyclonal antisera prepared against AC133 or any functional derivative thereof, have no cross-reactivity to others proteins. The monoclonal antibodies of the invention can for instance be produced by any hybridoma liable to be formed according to classical methods from splenic cells of an animal, particularly of a mouse or rat immunized against AC133 or any functional derivative thereof, and of cells of a myeloma cell line, and to be selected by the ability of the hybridoma to produce the monoclonal antibodies recognizing AC133 or any functional derivative thereof which have been initially used for the immunization of the animals. The monoclonal antibodies according to this embodiment of the invention may be humanized versions of the mouse monoclonal antibodies made by means of recombinant DNA technology, departing from the mouse and/or human genomic DNA sequences coding for H and L chains or from cDNA clones coding for H and L chains. Alternatively the monoclonal antibodies according to this embodiment of the invention may be human monoclonal antibodies. Such human monoclonal antibodies are prepared, for instance, by means of human peripheral blood lymphocytes (PBL) repopulation of severe combined immune deficiency (SCID) mice as described in PCT/EP 99/03605 or by using transgenic non-human animals capable of producing human antibodies as described

in US patent 5,545,866. Also fragments derived from these monoclonal antibodies such as Fab, F(ab)² and ssFv ("single chain variable fragment"), providing they have retained the original binding properties, form part of the present invention. Such fragments are commonly generated by, for instance, enzymatic digestion of the 5 antibodies with papain, pepsin, or other proteases. It is well known to the person skilled in the art that monoclonal antibodies, or fragments thereof, can be modified for various uses. The antibodies involved in the invention can be labeled by an appropriate label of the enzymatic, fluorescent, or radioactive type.

In a specific embodiment the antibodies against AC133 can be derived from animals 10 of the camelid family. In said family immunoglobulins devoid of light polypeptide chains are found. Heavy chain variable domain sequences derived from camelids are designated as VHH's. "Camelids" comprise old world camelids (*Camelus bactrianus* and *Camelus dromaderius*) and new world camelids (for example *Lama pacos*, *Lama glama* and *Lama vicugna*). EP0656946 describes the isolation and uses of camelid 15 immunoglobulins and is incorporated herein by reference.

Small molecules, e.g. small organic molecules, and other drug candidates can be obtained, for example, from combinatorial and natural product libraries.

Also within the scope of the invention are oligoribonucleotide sequences, that include 20 anti-sense RNA and DNA molecules and ribozymes that function to inhibit the translation of AC133 mRNA. Anti-sense RNA and DNA molecules act to directly block the translation of mRNA by binding to targeted mRNA and preventing protein translation. In regard to antisense DNA, oligodeoxyribonucleotides derived from the translation initiation site, e.g., between -10 and +10 regions of the AC133 nucleotide 25 sequence, are preferred. Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. The mechanism of ribozyme action involves sequence specific hybridization of the ribozyme molecule to complementary target RNA, followed by an endonucleolytic cleavage. Within the scope of the invention are engineered hammerhead motif ribozyme molecules that specifically and efficiently 30 catalyze endonucleolytic cleavage of AC133 RNA sequences.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences, GUA, GUU and GUC. Once identified, short RNA sequences of

between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for predicted structural features such as secondary structure that may render the oligonucleotide sequence unsuitable. The suitability of candidate targets may also be evaluated by testing their accessibility to 5 hybridization with complementary oligonucleotides, using ribonuclease protection assays.

Both anti-sense RNA and DNA molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of RNA molecules. These include techniques for chemically synthesizing oligodeoxyribonucleotides well known in 10 the art such as for example solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by *in vitro* and *in vivo* transcription of DNA sequences encoding the antisense RNA molecule. Such DNA sequences may be incorporated into a wide variety of vectors which incorporate suitable RNA polymerase 15 promoters such as the T7 or SP6 polymerase promoters. Alternatively, antisense cDNA constructs that synthesize anti-sense RNA constitutively or inducibly, depending on the promoter used, can be introduced stably into cell lines.

The term 'pathological angiogenesis' refers to the formation and growth of blood vessels during the maintenance and the progression of several disease states. 20 Examples where pathological angiogenesis can occur are blood vessels (atherosclerosis, hemangioma, hemangioendothelioma), bone and joints (rheumatoid arthritis, synovitis, bone and cartilage destruction, osteomyelitis, pannus growth, osteophyte formation, neoplasms and metastasis), skin (warts, pyogenic granulomas, hair growth, Kaposi's sarcoma, scar keloids, allergic oedema, neoplasms), liver, 25 kidney, lung, ear and other epithelia (inflammatory and infectious processes (including hepatitis, glomerulonephritis, pneumonia), asthma, nasal polyps, otitis, transplantation, liver regeneration, neoplasms and metastasis), uterus, ovary and placenta (dysfunctional uterine bleeding (due to intrauterine contraceptive devices), follicular cyst formation, ovarian hyperstimulation syndrome, endometriosis, neoplasms), brain, 30 nerves and eye (retinopathy of prematurity, diabetic retinopathy, choroidal and other intraocular disorders, leukomalacia, neoplasms and metastasis), heart and skeletal muscle due to work overload, adipose tissue (obesity), endocrine organs (thyroiditis, thyroid enlargement, pancreas transplantation), hematopoiesis (AIDS (Kaposi),

hematologic malignancies (leukemias, etc.), lymph vessels (tumour metastasis, lymphoproliferative disorders).

The term 'medicament to treat' relates to a composition comprising molecules as described above and a pharmaceutically acceptable carrier or excipient (both terms can be used interchangeably) to treat diseases as indicated above. Suitable carriers or excipients known to the skilled man are saline, Ringer's solution, dextrose solution, Hank's solution, fixed oils, ethyl oleate, 5% dextrose in saline, substances that enhance isotonicity and chemical stability, buffers and preservatives. Other suitable carriers include any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids and amino acid copolymers. The 'medicament' may be administered by any suitable method within the knowledge of the skilled man. The preferred route of administration is parenterally. In parental administration, the medicament of this invention will be formulated in a unit dosage injectable form such as a solution, suspension or emulsion, in association with the pharmaceutically acceptable excipients as defined above. However, the dosage and mode of administration will depend on the individual. Generally, the medicament is administered so that the protein, polypeptide, peptide of the present invention is given at a dose between 1 µg/kg and 10 mg/kg, more preferably between 10 µg/kg and 5 mg/kg, most preferably between 0.1 and 2 mg/kg. Preferably, it is given as a bolus dose. Continuous infusion may also be used and includes continuous subcutaneous delivery via an osmotic minipump. If so, the medicament may be infused at a dose between 5 and 20 µg/kg/minute, more preferably between 7 and 15 µg/kg/minute.

In another embodiment antibodies or functional fragments thereof can be used for the manufacture of a medicament for the treatment of the above mentioned disorders. As a non-limiting example there are the antibodies described in US 5,843,633. In a specific embodiment said antibodies are humanized (Rader et al., 2000, J. Biol. Chem. 275, 13668) and more specifically human antibodies are used to manufacture a medicament to treat pathological angiogenesis. In yet another specific embodiment antibodies derived from camelids are used to manufacture a medicament to treat pathological angiogenesis.

Another aspect of administration for treatment is the use of gene therapy to deliver the above mentioned anti-sense gene or functional parts of the AC133 gene or a ribozyme directed against the AC133 mRNA or a functional part thereof. Gene therapy means the treatment by the delivery of therapeutic nucleic acids to patient's cells. This is 5 extensively reviewed in Lever and Goodfellow 1995; Br. Med Bull., 51, 1-242; Culver 1995; Ledley, F.D. 1995. Hum. Gene Ther. 6, 1129. To achieve gene therapy there must be a method of delivering genes to the patient's cells and additional methods to ensure the effective production of any therapeutic genes. There are two general approaches to achieve gene delivery; these are non-viral delivery and virus-mediated 10 gene delivery.

The invention also provides methods for identifying compounds or molecules which bind on AC133 and prevent or suppress pathological angiogenesis. With "suppression" it is understood that said suppression can occur for at least 20%, 30%, 15 30%, 50%, 60%, 70%, 80%, 90% or even 100%.

Thus in another embodiment the invention provides a method to identify molecules that comprise a region that specifically binds to AC133 comprising: (1) exposing AC133 or nucleic acids encoding AC133 to at least one molecule whose ability to suppress or prevent pathological angiogenesis is sought to be determined, (2) determining binding or hybridising of said molecule(s) to AC133 or nucleic acids encoding AC133, and (3) monitoring said pathological angiogenesis when administering said molecules as a medicament.

The latter method is also referred to as 'drug screening assay' or 'bioassay' and typically include the step of screening a candidate/test compound or agent for the 25 ability to interact with AC133. Candidate compounds or agents, which have this ability, can be used as drugs to combat or prevent pathological conditions of angiogenesis. Candidate/test compounds such as small molecules, e.g. small organic molecules, and other drug candidates can be obtained, for example, from combinatorial and natural product libraries as described above.

30 Typically, the assays are cell-free assays which include the steps of combining AC133 and a candidate/test compound, e.g., under conditions which allow for interaction of (e.g. binding of) the candidate/test compound with AC133 to form a complex, and detecting the formation of a complex, in which the ability of the candidate compound to

interact with AC133 is indicated by the presence of the candidate compound in the complex. Formation of complexes between AC133 and the candidate compound can be quantitated, for example, using standard immunoassays. The AC133 employed in such a test may be free in solution, affixed to a solid support, borne on a cell surface, or located extracellularly or even intracellularly.

To perform the above described drug screening assays, it is feasible to immobilize AC133 or its (their) target molecule(s) to facilitate separation of complexes from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Interaction (e.g., binding of) of AC133 to a target molecule,

can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtitre plates, test tubes, and microcentrifuge tubes. In one embodiment, a fusion protein can be provided which adds a domain that allows the protein to be bound to a matrix. For example, AC133-His tagged can be adsorbed onto Ni-NTA microtitre plates, or AC133-ProtA fusions adsorbed to IgG, which are

then combined with the cell lysates (e.g., 35 S-labeled) and the candidate compound, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the plates are washed to remove any unbound label, and the matrix immobilized and radiolabel determined directly, or in the supernatant after the complexes are dissociated. Alternatively, the

complexes can be dissociated from the matrix, separated by SDS-PAGE, and the level of AC133-binding protein found in the bead fraction quantitated from the gel using standard electrophoretic techniques. Other techniques for immobilizing protein on matrices can also be used in the drug screening assays of the invention. For example, AC133 can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated

AC133 can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, Ill.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Another technique for drug screening which provides for high throughput screening of compounds having suitable binding affinity to AC133 is described in detail in

"Determination of Amino Acid Sequence Antigenicity" by Geysen HN, WO 84/03564, published on 13/09/84. In summary, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The protein test compounds are reacted with fragments of AC133 and washed. Bound AC133 is then detected by methods well known in the art. Purified

AC133 can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support. This invention also contemplates the use of competitive drug screening assays in which neutralizing 5 antibodies capable of binding AC133 specifically compete with a test compound for binding AC133. In this manner, the antibodies can be used to detect the presence of any protein, which shares one or more antigenic determinants with AC133.

Examples

10 1. Generation of a AC133 knock-out mouse

Targeted inactivation of the AC133 gene was achieved by deletion of exon 2 (containing the start codon). Briefly, a genomic BAC (bacterial artificial chromosome) containing the murine AC133 (14) was obtained from Research Genetics Inc (Huntsville, AL) after screening by PCR and hybridization. Mapping of the murine 15 AC133 homologue gene revealed that the first exon, which is 79 bp long, is separated from the second exon by an approximately 8 kb intron. It is the second exon (376 bp long) which contains the startcodon ATG. A BamHI fragment of 11.5 kb containing exon 2 was subcloned into the pUC18 plasmid. A targeting vector for inactivation of the AC133 gene, pPNT.AC133^{null}, was constructed consisting of, from 5' to 3': 1.2 kb 20 of 5' homology comprising the end of intron 1; a loxP-flanked *neomycin* gene; 5.5 kb from intron 2 as 3'-homology; and a *thymidine kinase* selection cassette outside of the regions of homology for counterselection against random integration events. The integrity of the construct was verified by restriction digestion and sequencing. The linearized targeting vector pPNT.AC133^{null} was electroporated in R1 ES cells and 25 targeted clones were identified by appropriate Southern blot analysis and used for morula aggregation to generate AC133 deficient chimeric and germline mice. AC133^{-/-} mice were born at the expected Mendelian frequency (~25% of 450 offspring from AC133^{+/+} breeding pairs). They appeared healthy and were fertile, irrespective of their genetic background (backgrounds tested: 50% Swiss/50% 129, 100% 129, 50% 30 C57Bl6/50% 129 and 50% NMRI/50% 129). We anticipated that AC133 might play a crucial role in hematopoiesis implying that the AC133^{-/-} embryo would die *in utero* either after the appearance of the primitive hematopoiesis (7.5 days post coitum, site:

yolk sac) or at the emergence of the definitive hematopoiesis (12.5 days post coitum, site: fetal liver). Surprisingly, however, embryonic development in AC133^{-/-} mice was normal. AC133^{-/-} embryos were not rescued by maternal AC133, as AC133^{-/-} embryos, sired by AC133^{+/+} as well as by AC133^{-/-} breeding pairs, developed normally. Also 5 postnatal physiological vascular development seemed normal since no vascular defects could be observed in the heart, kidneys, lungs and skeletal muscle during postnatal growth in AC133^{-/-} mice.

2. Impaired pathological angiogenesis in AC133 knock-out mice

10 In order to study the possible role of AC133 in pathological conditions of angiogenesis AC 133^{-/-} mice and their wild-type littermates were subjected to a mouse model of ischemic retinopathy. In this hyperoxia-induced retinopathy model, neonatal mice (with an immature retinal vasculature) are exposed to hyperoxia, resulting in obliteration of the developing blood vessels supplying oxygen to the retina. When the mice are then 15 returned to normoxia, the retina, distal to the occluded vessels, becomes ischemic, inducing VEGF production and ultimately resulting in reproducible and quantifiable proliferative retinal neovascularization (29, 30). This model, which mimicks to a certain extent the vascular response during retinopathy of prematurity or diabetic retinopathy, may be useful to test the efficacy of (anti)-angiogenic molecules (31). Mouse pups of 7 20 days (P7) together with their mothers, are subjected to hyperoxia (75% oxygen) in specially designed oxygen chambers for 5 days, without opening the cages. On P12, the animals are returned to room air until P17, when the retinas are assessed for maximal neovascular response. Anesthetized mice are perfused through the left ventricle with 1 ml of phosphate buffered saline containing 50 mg of 2x10⁶ molecular 25 weight fluorescein-dextran. The eyes are removed and fixed in 4% paraformaldehyde for 3 (right eye) or 24 (left eye) hrs. Of the right eyes, lenses are removed and peripheral retinas cut to allow flat mounting with glycerol-gelatin. The flat mounted retinas are analyzed by fluorescence microscopy. The left eyes are embedded in paraffin and serial 6 µm sections are cut sagittally throughout the cornea, parallel to 30 the optic nerve, and stained with hematoxylin-eosin. The proliferative neovascular response is quantified by counting the number of new vessels (= tufts) and the number of endothelial cells extending from the internal limiting membrane of the retina into the vitreum on the stained sagittal cross-sections. The angiographic technique using

fluorescein-dextran perfusion is used in conjunction with this counting method for rapid screening of retinas or as an alternative grading system for quantitative evaluation.

Loss of AC133 significantly protected mice against intra-vitreous neovascularization, as evaluated by counting the number of neovascular tufts and endothelial cells (EC) in
5 the vitreous cavity (n=15; p<0.001)

	N° of tufts in vitreous cavity (per 10 retinal sections)	N° of EC in vitreous cavity (per 10 retinal sections)
AC133 ^{+/+} pups (n = 15)	157.1 ± 13.6	286.0 ± 45.1
AC133 ^{-/-} pups (n = 15)	72.5 ± 14.6	106.2 ± 22.6

The effect of (anti)-angiogenic molecules has been frequently studied in the corneal micropocket assay [Kenyon, 1996]. Implantation of hydron pellets containing angiogenic factors in the stroma of the avascular mouse cornea allows screening of the angiogenic response in the absence of inflammation. As the cornea in the mouse is thinner than in other species, growth of new blood vessels largely occurs in a two-dimensional plane. Hydron pellets containing an angiogenic substance (like bFGF or VEGF) are implanted into the corneal stroma adjacent to the temporal limbus. This induces neovascularization of the avascular corneal stroma from day 3 to day 8 after implantation, without substantial corneal edema or inflammation. Like the retinal hypoxia model, it gives a predictable, persistent and aggressive neovascular response, which is dependent on direct stimulation of blood vessels rather than on indirect stimulation by the induction of inflammation [Kenyon, 1996]. The mouse
10 corneal micropocket assay was performed as previously described [Asahara, 1998]. Hydron-coated sucralfate pellets containing 300 ng of VEGF₁₆₅ were positioned 1 mm from the corneal limbus. Corneal angiogenesis was evaluated six days after implantation of hydron pellets. Anesthetized mice were perfused through the left ventricle with 1 ml of phosphate buffered saline containing 50 mg of 2x10⁶ molecular weight fluorescein-dextran. The eyes were removed and fixed in 4% paraformaldehyde for 3 hrs. Corneas were peeled off and flat mounted with glycerol-gelatin. Vessel length, the arc of circumference occupied by neovascularity
15
20
25

(circumferential neovascularity) and the integrated optical density of the area occupied by new vessels was determined by fluorescence microscopy and image analysis.

Mice deficient for AC133 showed a reduced angiogenic response. Despite a comparable length of the newly formed vessels, the circumferential neovascularity and 5 the integrated optical density of the vessel area were significantly lower in the AC133 mice (n=7; p<0.05).

	Vessel length (μm)	Circumferential neovascularity (μm)	Integrated optical density of the vessel area
AC133 ^{+/+} pups (n = 7)	5.3 ± 0.6	41.7 ± 3.0	430 ± 58
AC133 ^{-/-} pups (n = 7)	5.1 ± 0.7	28.9 ± 3.5 *	302 ± 37 *

10 Vascular remodeling was also studied in a model of skin wound healing as described before [Frank, 1995; Carmeliet, 2001]. For skin wounding, a standardised 15 mm full-thickness skin incision was made on the back of the mice, taking care not to damage the underlying muscle. Wound healing was quantified by daily measurements of the width and the length of the wound. New blood vessel formation was analysed on skin 15 sections harvested four days after wounding. Using antibodies to CD31, which labels endothelial cells, and antibodies to smooth muscle alpha actin, labeling smooth muscle cells, the number of new vessels and of new vessels covered with SMC were analysed. Both genotypes contained comparable densities of vessels in unwounded skin. However, the number of capillaries infiltrating the wound as well as the number 20 of smooth muscle-coated vessels in the wounded area were significantly reduced in AC133 deficient mice (n=5; p<0.05).

	Capillary density in wounded area (/ mm^2)	Density of SMC coated vessels (/ mm^2)
AC133 ^{+/+} pups (n = 5)	±	53.4 ± 5.9
AC133 ^{-/-} pups (n = 5)	±	28.6 ± 2.7 *

References

1. Risau W. Mechanisms of angiogenesis. *Nature* 1997;386(6626):671-4.
2. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. *Science* 1997;275(5302):964-7.
- 5 3. Shi Q, Rafii S, Wu MH, Wijelath ES, Yu C, Ishida A, et al. Evidence for circulating bone marrow-derived endothelial cells. *Blood* 1998;92(2):362-7.
4. Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. *Nat Med* 1999;5(4):434-8.
- 10 5. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. *Circ Res* 1999;85(3):221-8.
- 15 6. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. *Embo J* 1999;18(14):3964-72.
7. Bhattacharya V, McSweeney PA, Shi Q, Bruno B, Ishida A, Nash R, et al. Enhanced endothelialization and microvessel formation in polyester grafts seeded with CD34(+) bone marrow cells. *Blood* 2000;95(2):581-5.
- 20 8. Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. *Proc Natl Acad Sci U S A* 2000;97(7):3422-7.
9. Schatteman GC, Hanlon HD, Jiao C, Dodds SG, Christy BA. Blood-derived angioblasts accelerate blood-flow restoration in diabetic mice. *J Clin Invest* 2000;106(4):571-8.
- 25 10. Kawamoto A, Gwon HC, Iwaguro H, Yamaguchi JI, Uchida S, Masuda H, et al. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. *Circulation* 2001;103(5):634-7.
11. Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J, et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. *Nat Med* 2001;7(4):430-6.
- 30

12. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. *Circ Res* 2001;89(1):E1-7.
- 5 13. Gill M, Dias S, Hattori K, Rivera ML, Hicklin D, Witte L, et al. Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells. *Circ Res* 2001;88(2):167-74.
- 10 14. Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, Holden JT, et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. *Blood* 1997;90(12):5013-21.
- 15 15. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. *Blood* 1997;90(12):5002-12.
16. de Wynter EA, Buck D, Hart C, Heywood R, Coutinho LH, Clayton A, et al. CD34+AC133+ cells isolated from cord blood are highly enriched in long-term culture-initiating cells, NOD/SCID-repopulating cells and dendritic cell progenitors. *Stem Cells* 1998;16(6):387-96.
- 20 17. Buhring HJ, Seiffert M, Bock TA, Scheding S, Thiel A, Scheffold A, et al. Expression of novel surface antigens on early hematopoietic cells. *Ann NY Acad Sci* 1999;872:25-38; discussion 38-9.
18. Horn PA, Tesch H, Staib P, Kube D, Diehl V, Voliotis D. Expression of AC133, a novel hematopoietic precursor antigen, on acute myeloid leukemia cells. *Blood* 1999;93(4):1435-7.
- 25 19. Kratz-Albers K, Zuhlsdorp M, Leo R, Berdel WL, Buchner T, Serve H. Expression of a AC133, a novel stem cell marker, on human leukemic blasts lacking CD34- antigen and on a human CD34+ leukemic line: MUTZ-2. *Blood* 1998;92(11):4485-7.
20. Buhring HJ, Seiffert M, Marxer A, Weiss B, Faul C, Kanz L, et al. AC133 antigen expression is not restricted to acute myeloid leukemia blasts but is also found on acute lymphoid leukemia blasts and on a subset of CD34+ B-cell precursors. *Blood* 1999;94(2):832-3.
- 30 21. Corbeil D, Roper K, Hannah MJ, Hellwig A, Huttner WB. Selective localization of the polytopic membrane protein prominin in microvilli of epithelial cells - a combination of apical sorting and retention in plasma membrane protrusions. *J Cell Sci* 1999;112(Pt 7):1023-33.

22. Gehling UM, Ergun S, Schumacher U, Wagener C, Pantel K, Otte M, et al. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. *Blood* 2000;95(10):3106-12.
- 5 23. Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. *Blood* 2000;95(3):952-8.
- 10 24. Quirici N, Soligo D, Caneva L, Servida F, Bossolasco P, Deliliers GL. Differentiation and expansion of endothelial cells from human bone marrow CD133(+) cells. *Br J Haematol* 2001;115(1):186-94.
- 15 25. Corbeil D, Roper K, Weigmann A, Huttner WB. AC133 hematopoietic stem cell antigen: human homologue of mouse kidney prominin or distinct member of a novel protein family? *Blood* 1998;91(7):2625-6.
26. Miraglia S, Godfrey W, Buck D. A response to AC133 hematopoietic stem cell antigen: human homologue of mouse kidney prominin or distinct member of a novel protein family? *Blood* 1998;91(11):4390-1.
- 15 27. Wilson R, Ainscough R, Anderson K, Baynes C, Berks M, Bonfield J, et al. 2.2 Mb of contiguous nucleotide sequence from chromosome III of *C. elegans*. *Nature* 1994;368(6466):32-8.
- 20 28. Weigmann A, Corbeil D, Hellwig A, Huttner WB. Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells. *Proc Natl Acad Sci U S A* 1997;94(23):12425-30.
- 25 29. Smith LE, Wesolowski E, McLellan A, Kostyk SK, D'Amato R, Sullivan R, et al. Oxygen-induced retinopathy in the mouse. *Invest Ophthalmol Vis Sci* 1994;35(1):101-11.
- 30 30. Wesolowski E, Smith LE. Effect of light on oxygen-induced retinopathy in the mouse. *Invest Ophthalmol Vis Sci* 1994;35(1):112-9.
31. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. *Proc Natl Acad Sci U S A* 1995;92(3):905-9.

07. 2002

Claims

(65)

1. Use of a molecule which comprises a region specifically binding to AC133 or nucleic acids encoding AC133, for the manufacture of a medicament to treat pathological angiogenesis.

5

2. Use according to claim 1 wherein said molecule is chosen from the list comprising an antibody or any fragment thereof binding to AC133, a small molecule specifically binding to AC133 or nucleic acids encoding AC133, a ribozyme against nucleic acids encoding AC133, and anti-sense nucleic acids hybridising with nucleic acids encoding AC133.

10

3. A method to identify molecules that comprise a region that specifically binds to AC133 comprising:

- 15
- exposing AC133 or nucleic acids encoding AC133 to at least one molecule whose ability to suppress or prevent pathological angiogenesis is sought to be determined,
 - determining binding or hybridising of said molecule(s) to AC133 or nucleic acids encoding AC133, and
 - monitoring said pathological angiogenesis when administering said molecules as a medicament.
- 20

25

30

Abstract

The invention relates to the field of pathological angiogenesis. In particular the invention relates to the use of molecules binding to AC133 that can be used for the manufacture of a medicament to prevent angiogenesis.

5


EPO - DG 1

12. 07. 2002

(65)

1/1

Fig. 1: Healing of wounds in AC133 deficient mice and wild-type littermates



These data clearly indicate a role of AC 133 in pathological vasculogenesis and/or angiogenesis and implicate the use of inhibitors of AC133 in therapeutic strategies to inhibit blood vessel formation in various pathological disorders.

EPO - DG 1

12. 07. 2002

(65)

12. 07. 2002

65

<110> VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW

<120> A NOVEL TARGET TO INHIBIT ANGIOGENESIS

<130> PCA/AC133/123

<160> 2

<170> PatentIn version 3.1

<210> 1

<211> 3794

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (38)..(2635)

<223>

<400>	1	ccaagttctta cctcatgttt ggaggatctt gctagct	atg	gcc	ctc	gta	ctc	ggc	55							
			Met	Ala	Leu	Val	Leu	Gly								
	1						5									
tcc	ctg	ttg	ctg	ctg	ggg	ctg	tgc	ggg	aac	tcc	ttt	tca	gga	ggg	cag	103
Ser	Leu	Leu	Leu	Leu	Gly	Leu	Cys	Gly	Asn	Ser	Phe	Ser	Gly	Gly	Gln	
	10				15					20						
cct	tca	tcc	aca	gat	gct	cct	aag	gct	tgg	aat	tat	gaa	ttg	cct	gca	151
Pro	Ser	Ser	Thr	Asp	Ala	Pro	Lys	Ala	Trp	Asn	Tyr	Glu	Leu	Pro	Ala	
	25				30					35						
aca	aat	tat	gag	acc	caa	gac	tcc	cat	aaa	gct	gga	ccc	att	ggc	att	199
Thr	Asn	Tyr	Glu	Thr	Gln	Asp	Ser	His	Lys	Ala	Gly	Pro	Ile	Gly	Ile	
	40			45					50							
ctc	ttt	gaa	cta	gtg	cat	atc	ttt	ctc	tat	gtg	gta	cag	ccg	cgt	gat	247
Leu	Phe	Glu	Leu	Val	His	Ile	Phe	Leu	Tyr	Val	Val	Gln	Pro	Arg	Asp	
	55			60					65							
ttc	cca	gaa	gat	act	ttg	aga	aaa	ttc	tta	cag	aag	gca	tat	gaa	tcc	295
Phe	Pro	Glu	Asp	Thr	Leu	Arg	Lys	Phe	Leu	Gln	Lys	Ala	Tyr	Glu	Ser	
	75			80									85			
aaa	att	gat	tat	gac	aag	cca	gaa	act	gta	atc	tta	ggt	cta	aag	att	343
Lys	Ile	Asp	Tyr	Asp	Lys	Pro	Glu	Thr	Val	Ile	Leu	Gly	Leu	Lys	Ile	
	90			95						100						
gtc	tac	tat	gaa	gca	ggg	att	att	cta	tgc	tgt	gtc	ctg	ggg	ctg	ctg	391
Val	Tyr	Tyr	Glu	Ala	Cly	Tle	Tle	Leu	Cys	Cys	Val	Leu	Cly	Cys	Leu	

		123.ST25	
105	110	115	
ttt att att ctg atg cct ctg gtg ggg tat ttc ttt tgt atg tgt cgt Phe Ile Ile Leu Met Pro Leu Val Gly Tyr Phe Phe Cys Met Cys Arg	120 125	130	439
tgc tgt aac aaa tgt ggt gga gaa atg cac cag cga cag aag gaa aat Cys Cys Asn Lys Cys Gly Gly Glu Met His Gln Arg Gln Lys Glu Asn	135 140	145	487
ggg ccc ttc ctg agg aaa tgc ttt gca atc tcc ctg ttg gtg att tgt Gly Pro Phe Leu Arg Lys Cys Phe Ala Ile Ser Leu Leu Val Ile Cys	155 160	165	535
ata ata ata agc att ggc atc ttc tat ggt ttt gtg gca aat cac cag Ile Ile Ile Ser Ile Gly Ile Phe Tyr Gly Phe Val Ala Asn His Gln	170 175	180	583
gta aga acc cggtt atc aaa agg agt cgg aaa ctg gca gat agc aat ttc Val Arg Thr Arg Ile Lys Arg Ser Arg Lys Leu Ala Asp Ser Asn Phe	185 190	195	631
aag gac ttg cga act ctc ttg aat gaa act cca gag caa atc aaa tat Lys Asp Leu Arg Thr Leu Leu Asn Glu Thr Pro Glu Gln Ile Lys Tyr	200 205	210	679
ata ttg gcc cag tac aac act acc aag gac aag gcg ttc aca gat ctg Ile Leu Ala Gln Tyr Ash Thr Lys Asp Lys Ala Phe Thr Asp Leu	215 220	225	727
aac agt atc aat tca gtg cta gga ggc gga att ctt gac cga ctg aga Asn Ser Ile Asn Ser Val Leu Gly Gly Ile Leu Asp Arg Leu Arg	235 240	245	775
ccc aac atc atc cct gtt ctt gat gag att aag tcc atg gca aca gcg Pro Asn Ile Ile Pro Val Leu Asp Glu Ile Lys Ser Met Ala Thr Ala	250 255	260	823
atc aag gag acc aaa gag gcg ttg gag aac atg aac agc acc ttg aag Ile Lys Glu Thr Lys Glu Ala Leu Glu Asn Met Asn Ser Thr Leu Lys	265 270	275	871
agc ttg cac caa caa agt aca cag ctt agc agc agt ctg acc agc gtg Ser Leu His Gln Gln Ser Thr Gln Leu Ser Ser Ser Leu Thr Ser Val	280 285	290	919
aaa act agc ctg cgg tca tct ctc aat gac cct ctg tgc ttg gtg cat Lys Thr Ser Leu Arg Ser Ser Leu Asn Asp Pro Leu Cys Leu Val His	295 300	305	967
cca tca agt gaa acc tgc aac agc atc aga ttg tct cta agc cag ctg Pro Ser Ser Glu Thr Cys Asn Ser Ile Arg Leu Ser Leu Ser Gln Leu	315 320	325	1015
aat agc aac cct gaa ctg agg cag ctt cca ccc gtg gat gca gaa ctt Asn Ser Asn Pro Glu Leu Arg Gln Leu Pro Pro Val Asp Ala Glu Leu	330 335	340	1063
gac aac gtt aat aac gtt ctt agg aca gat ttg gat ggc ctg gtc caa Asp Asn Val Asn Asn Val Leu Arg Thr Asp Leu Asp Gly Leu Val Gln	345 350	355	1111
cag ggc tat caa tcc ctt aat gat ata cct gac aga gta caa cgc caa Gln Gly Tyr Gln Ser Leu Asn Asp Ile Pro Asp Arg Val Gln Arg Gln	360 365	370	1159
acc acg act gtc gta gca ggt atc aaa agg gtc ttg aat tcc att ggt Thr Thr Thr Val Val Ala Gly Ile Lys Arg Val Leu Asn Ser Ile Gly	375 380	385	1207
tca gat atc gac aat gta act cag cgt ctt cct att cag gat ata ctc Ser Asp Ile Asp Asn Val Thr Gln Arg Leu Pro Ile Gln Asp Ile Leu	395 400	405	1255
tca gca ttc tct gtt tat gtt aat aac act gaa agt tac atc cac aga			1303

123.ST25

Ser Ala Phe Ser Val Tyr Val Asn Asn Thr Glu Ser Tyr Ile His Arg
 410 415 420
 aat tta cct aca ttg gaa gag tat gat tca tac tgg tgg ctg ggt ggc 1351
 Asn Leu Pro Thr Leu Glu Glu Tyr Asp Ser Tyr Trp Trp Leu Gly Gly
 425 430 435
 ctg gtc atc tgc tct ctg ctg acc ctc atc gtg att ttt tac tac ctg 1399
 Leu Val Ile Cys Ser Leu Leu Thr Leu Ile Val Ile Phe Tyr Tyr Leu
 440 445 450
 ggc tta ctg tgt ggc gtg tgc ggc tat gac agg cat gcc acc ccg acc 1447
 Gly Leu Leu Cys Gly Val Cys Gly Tyr Asp Arg His Ala Thr Pro Thr
 455 460 465 470
 acc cga ggc tgt gtc tcc aac acc gga ggc gtc ttc ctc atg gtt gga 1495
 Thr Arg Gly Cys Val Ser Ash Thr Gly Gly Val Phe Leu Met Val Gly
 475 480 485
 gtt gga tta agt ttc ctc ttt tgc tgg ata ttg atg atc att gtg gtt 1543
 Val Gly Leu Ser Phe Leu Phe Cys Trp Ile Leu Met Ile Ile Val Val
 490 495 500
 ctt acc ttt gtc ttt ggt gca aat gtg gaa aaa ctg atc tgt gaa cct 1591
 Leu Thr Phe Val Phe Gly Ala Asn Val Glu Lys Leu Ile Cys Glu Pro
 505 510 515
 tac acg agc aag gaa tta ttc cgg gtt ttg gat aca ccc tac tta cta 1639
 Tyr Thr Ser Lys Glu Leu Phe Arg Val Leu Asp Thr Pro Tyr Leu Leu
 520 525 530
 aat gaa gac tgg gaa tac tat ctc tct ggg aag cta ttt aat aaa tca 1687
 Asn Glu Asp Trp Glu Tyr Tyr Leu Ser Gly Lys Leu Phe Asn Lys Ser
 535 540 545 550
 aaa atg aag ctc act ttt gaa caa gtt tac agt gac tgc aaa aaa aat 1735
 Lys Met Lys Leu Thr Phe Glu Gln Val Tyr Ser Asp Cys Lys Lys Asn
 555 560 565
 aga ggc act tac ggc act ctt cac ctg cag aac agc ttc aat atc agt 1783
 Arg Gly Thr Tyr Gly Thr Leu His Leu Gln Asn Ser Phe Asn Ile Ser
 570 575 580
 gaa cat ctc aac att aat gag cat act gga agc ata agc agt gaa ttg 1831
 Glu His Leu Asn Ile Asn Glu His Thr Gly Ser Ile Ser Ser Glu Leu
 585 590 595
 gaa agt ctg aag gta aat ctt aat atc ttt ctg ttg ggt gca gca gga 1879
 Glu Ser Leu Lys Val Asn Leu Asn Ile Phe Leu Leu Gly Ala Ala Gly
 600 605 610
 aga aaa aac ctt cag gat ttt gct gct tgt gga ata gac aga atg aat 1927
 Arg Lys Asn Leu Gln Asp Phe Ala Ala Cys Gly Ile Asp Arg Met Asn
 615 620 625 630
 tat gac agc tac ttg gct cag act ggt aaa tcc ccc gca gga gtg aat 1975
 Tyr Asp Ser Tyr Leu Ala Gln Thr Gly Lys Ser Pro Ala Gly Val Asn
 635 640 645
 ctt tta tca ttt gca tat gat cta gaa gca aaa gca aac agt ttg ccc 2023
 Leu Leu Ser Phe Ala Tyr Asp Leu Glu Ala Lys Ala Asn Ser Leu Pro
 650 655 660
 cca gga aat ttg agg aac tcc ctg aaa aga gat gca caa act att aaa 2071
 Pro Gly Asn Leu Arg Asn Ser Leu Lys Arg Asp Ala Gln Thr Ile Lys
 665 670 675
 aca att cac cag caa cga gtc ctt cct ata gaa caa tca ctg agc act 2119
 Thr Ile His Gln Gln Arg Val Leu Pro Ile Glu Gln Ser Leu Ser Thr
 680 685 690
 cta tac caa agc gtc aag ata ctt caa cgc aca ggg aat gga ttg ttg 2167
 Leu Tyr Gln Ser Val Lys Ile Leu Gln Arg Thr Gly Asn Gly Leu Leu
 695 700 705 710

123.ST25

gag aga gta act agg att cta gct tct ctg gat ttt gct cag aac ttc Glu Arg Val Thr Arg Ile Leu Ala Ser Leu Asp Phe Ala Gln Asn Phe 715 720 725	2215
atc aca aac aat act tcc tct gtt att att gag gaa act aag aag tat Ile Thr Asn Asn Thr Ser Ser Val Ile Ile Glu Glu Thr Lys Lys Tyr 730 735 740	2263
ggg aga aca ata ata gga tat ttt gaa cat tat ctg cag tgg atc gag Gly Arg Thr Ile Ile Gly Tyr Phe Glu His Tyr Leu Gln Trp Ile Glu 745 750 755	2311
ttc tct atc agt gag aaa gtg gca tcg tgc aaa cct gtg gcc acc gct Phe Ser Ile Ser Glu Lys Val Ala Ser Cys Lys Pro Val Ala Thr Ala 760 765 770	2359
cta gat act gct gtt gat gtc ttt ctg tgt agc tac att atc gac ccc Leu Asp Thr Ala Val Asp Val Phe Leu Cys Ser Tyr Ile Ile Asp Pro 775 780 785 790	2407
ttg aat ttg ttt tgg ttt ggc ata gga aaa gct act gta ttt tta ctt Leu Asn Leu Phe Trp Phe Gly Ile Gly Lys Ala Thr Val Phe Leu Leu 795 800 805	2455
ccg gct cta att ttt gcg gta aaa ctg gct aag tac tat cgt cga atg Pro Ala Leu Ile Phe Ala Val Lys Leu Ala Lys Tyr Tyr Arg Arg Met 810 815 820	2503
gat tcg gag gac gtg tac gat gat gtt gaa act ata ccc atg aaa aat Asp Ser Glu Asp Val Tyr Asp Asp Val Glu Thr Ile Pro Met Lys Asn 825 830 835	2551
atg gaa aat ggt aat aat ggt tat cat aaa gat cat gta tat ggt att Met Glu Asn Gly Asn Asn Gly Tyr His Lys Asp His Val Tyr Gly Ile 840 845 850	2599
cac aat cct gtt atg aca agc cca tca caa cat tga tagctgatgt His Asn Pro Val Met Thr Ser Pro Ser Gln His	2645
855 860 865	
tgaaactgct tgagcatca gatactaaa gtggaaagga tcacagattt ttggtagttt ctgggtctac aaggactttc caaatccagg agcaacgcca gtggcaacgt agtgactcag	2705
gcgggcacca aggcaacggc accattggc tctgggtagt gcttaagaa tgaacacaat cacgttatag tccatggtcc atcaactattc aaggatgact ccctcccttc ctgtctattt	2765
ttgttttta ctttttaca ctgagttct atttagacac tacaacatat ggggtgtttg ttcccattgg atgcattttc atcaaaactc tatcaaatgt gatggctaga ttctaacata	2825
ttgccatgtg tggagtgtgc tgaacacaca ccagtttaca ggaaagatgc attttgtgt cagtaaacgg tgtatatacc ttttgttacc acagagttt ttaaacaat gagtattata	2885
ggactttctt ctaaatgagc taaataagtc accattgact tcttggtgct gttgaaaata atccattttc actaaaagtg tgtgaaacct acagcatatt cttcacgcag agattttcat	3005
ctattatact ttatcaaaga ttggccatgt tccacttgg aatggcatgc aaaagccatc atagagaaac ctgcgtaact ccatctgaca aattcaaaag agagagagag atcttgagag	3065
agaaaatgctg ttcgttcaaa agtggagttg ttttacaga tgccaattac ggtgtacagt ttaacagagt tttctgttgc attaggataa acattaattg gagtgcagct aacatgagta	3125
tcatcagact agtatcaagt gttctaaaat gaaatatgag aagatccctgt cacaattctt agatctggtg tccagcatgg atgaaacctt tgagtttggt ccctaaattt gcatgaaagc	3185
acaaggtaaa tattcatttg cttcaggagt ttcatgttgg atctgtcatt atcaaaaagtg atcagcaatg aagaactggt cggacaaaat ttaacgttga tctaattggaa ttccagatgt	3245
	3205
	3305
	3365
	3425
	3485
	3545
	3605
	3665
	3725

123.ST25

aggcattccc cccaggtctt ttcatgtgca gattgcagtt ctgattcatt tgaataaaaa 3785
ggaacttgg 3794

<210> 2

<211> 865

<212> PRT

<213> Homo sapiens

<400> 2

Met Ala Leu Val Leu Gly Ser Leu Leu Leu Gly Leu Cys Gly Asn
1 5 10 15

Ser Phe Ser Gly Gly Gln Pro Ser Ser Thr Asp Ala Pro Lys Ala Trp
20 25 30

Asn Tyr Glu Leu Pro Ala Thr Asn Tyr Glu Thr Gln Asp Ser His Lys
35 40 45

Ala Gly Pro Ile Gly Ile Leu Phe Glu Leu Val His Ile Phe Leu Tyr
50 55 60

Val Val Gln Pro Arg Asp Phe Pro Glu Asp Thr Leu Arg Lys Phe Leu
65 70 75 80

Gln Lys Ala Tyr Glu Ser Lys Ile Asp Tyr Asp Lys Pro Glu Thr Val
85 90 95

Ile Leu Gly Leu Lys Ile Val Tyr Tyr Glu Ala Gly Ile Ile Leu Cys
100 105 110

Cys Val Leu Gly Leu Leu Phe Ile Ile Leu Met Pro Leu Val Gly Tyr
115 120 125

Phe Phe Cys Met Cys Arg Cys Cys Asn Lys Cys Gly Gly Glu Met His
130 135 140

Gln Arg Gln Lys Glu Asn Gly Pro Phe Leu Arg Lys Cys Phe Ala Ile
145 150 155 160

Ser Leu Leu Val Ile Cys Ile Ile Ile Ser Ile Gly Ile Phe Tyr Gly
165 170 175

Phe Val Ala Asn His Gln Val Arg Thr Arg Ile Lys Arg Ser Arg Lys
180 185 190

Leu Ala Asp Ser Asn Phe Lys Asp Leu Arg Thr Leu Leu Asn Glu Thr
195 200 205

Pro Glu Gln Ile Lys Tyr Ile Leu Ala Gln Tyr Asn Thr Thr Lys Asp
210 215 220

Lys Ala Phe Thr Asp Leu Asn Ser Ile Asn Ser Val Leu Gly Gly Gly

123.ST25

225	230	235	240
Ile Leu Asp Arg Leu Arg Pro Asn Ile	Ile Pro Val Leu Asp Glu Ile		
245	250	255	
Lys Ser Met Ala Thr Ala Ile Lys	Glu Thr Lys Glu Ala Leu Glu Asn		
260	265	270	
Met Asn Ser Thr Leu Lys Ser Leu	His Gln Gln Ser Thr Gln Leu Ser		
275	280	285	
Ser Ser Leu Thr Ser Val Lys	Thr Ser Leu Arg Ser Ser Leu Asn Asp		
290	295	300	
Pro Leu Cys Leu Val His	Pro Ser Ser Glu Thr Cys Asn Ser Ile Arg		
305	310	315	320
Leu Ser Leu Ser Gln	Leu Asn Ser Asn Pro Glu Leu Arg Gln Leu Pro		
325	330	335	
Pro Val Asp Ala Glu Leu Asp Asn Val	Asn Asn Val Leu Arg Thr Asp		
340	345	350	
Leu Asp Gly Leu Val Gln Gln	Gly Tyr Gln Ser Leu Asn Asp Ile Pro		
355	360	365	
Asp Arg Val Gln Arg Gln	Thr Thr Thr Val Val Ala Gly Ile Lys Arg		
370	375	380	
Val Leu Asn Ser Ile Gly	Ser Asp Ile Asp Asn Val Thr Gln Arg Leu		
385	390	395	400
Pro Ile Gln Asp Ile	Leu Ser Ala Phe Ser Val Tyr Val Asn Asn Thr		
405	410	415	
Glu Ser Tyr Ile His Arg Asn Leu	Pro Thr Leu Glu Glu Tyr Asp Ser		
420	425	430	
Tyr Trp Trp Leu Gly	Gly Leu Val Ile Cys Ser Leu Leu Thr Leu Ile		
435	440	445	
Val Ile Phe Tyr Tyr Leu Gly	Leu Leu Cys Gly Val Cys Gly Tyr Asp		
450	455	460	
Arg His Ala Thr Pro Thr	Thr Arg Gly Cys Val Ser Asn Thr Gly Gly		
465	470	475	480
Val Phe Leu Met Val	Gly Val Gly Leu Ser Phe Leu Phe Cys Trp Ile		
485	490	495	
Leu Met Ile Ile Val Val	Leu Thr Phe Val Phe Gly Ala Asn Val Glu		
500	505	510	
Lys Leu Ile Cys Glu Pro Tyr	Thr Ser Lys Glu Leu Phe Arg Val Leu		
515	520	525	

123.ST25

Asp Thr Pro Tyr Leu Leu Asn Glu Asp Trp Glu Tyr Tyr Leu Ser Gly
530 535 540 545

Lys Leu Phe Asn Lys Ser Lys Met Lys Leu Thr Phe Glu Gln Val Tyr
550 555 560

Ser Asp Cys Lys Lys Asn Arg Gly Thr Tyr Gly Thr Leu His Leu Gln
565 570 575

Asn Ser Phe Asn Ile Ser Glu His Leu Asn Ile Asn Glu His Thr Gly
580 585 590

Ser Ile Ser Ser Glu Leu Glu Ser Leu Lys Val Asn Leu Asn Ile Phe
595 600 605

Leu Leu Gly Ala Ala Gly Arg Lys Asn Leu Gln Asp Phe Ala Ala Cys
610 615 620

Gly Ile Asp Arg Met Asn Tyr Asp Ser Tyr Leu Ala Gln Thr Gly Lys
625 630 635 640

Ser Pro Ala Gly Val Asn Leu Leu Ser Phe Ala Tyr Asp Leu Glu Ala
645 650 655

Lys Ala Asn Ser Leu Pro Pro Gly Asn Leu Arg Asn Ser Leu Lys Arg
660 665 670

Asp Ala Gln Thr Ile Lys Thr Ile His Gln Gln Arg Val Leu Pro Ile
675 680 685

Glu Gln Ser Leu Ser Thr Leu Tyr Gln Ser Val Lys Ile Leu Gln Arg
690 695 700

Thr Gly Asn Gly Leu Leu Glu Arg Val Thr Arg Ile Leu Ala Ser Leu
705 710 715 720

Asp Phe Ala Gln Asn Phe Ile Thr Asn Asn Thr Ser Ser Val Ile Ile
725 730 735

Glu Glu Thr Lys Lys Tyr Gly Arg Thr Ile Ile Gly Tyr Phe Glu His
740 745 750

Tyr Leu Gln Trp Ile Glu Phe Ser Ile Ser Glu Lys Val Ala Ser Cys
755 760 765

Lys Pro Val Ala Thr Ala Leu Asp Thr Ala Val Asp Val Phe Leu Cys
770 775 780

Ser Tyr Ile Ile Asp Pro Leu Asn Leu Phe Trp Phe Gly Ile Gly Lys
785 790 795 800

Ala Thr Val Phe Leu Leu Pro Ala Leu Ile Phe Ala Val Lys Leu Ala
805 810 815

Lys Tyr Tyr Arg Arg Met Asp Ser Glu Asp Val Tyr Asp Asp Val Glu
820 825 830

123.ST25

Thr Ile Pro Met Lys Asn Met Glu Asn Gly Asn Asn Gly Tyr His Lys
835 840 845

Asp His Val Tyr Gly Ile His Asn Pro Val Met Thr Ser Pro Ser Gln
850 855 860

His
865

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.